A novel IkB kinase inhibitor attenuates ligature-induced periodontal disease in mice

J Periodontal Res. 2019 Apr;54(2):164-173. doi: 10.1111/jre.12615. Epub 2018 Oct 8.

Abstract

Backgrounds and objectives: IMD-0354 is a novel I kappa-B kinase (IKK) inhibitor, which regulates inflammation. The purpose of this study was to examine the effect of the reagent on bone loss for ligature-induced periodontitis.

Material and methods: We ligated around the upper right second molars of 8-week-old C57BL/6J mice in the split-mouth model. The test mice were injected intraperitoneally with IMD-0354 before the placement of the ligature. The control mice were injected intraperitoneally with 0.5% carboxymethylcellulose (CMC) as vehicle before the placement of the ligature. To determine the optimum concentration of the reagent on ligature-induced periodontitis in the mice, we examined the effect of three types of concentration, which were 1, 5, and 10 mg/kg of IMD-0354, as a preliminary experiment. After we determined 10 mg/kg as the optimum concentration for the IMD group by micro-CT analysis, both the IMD and CMC groups (n = 15 each in total, including all the analyses) were subdivided into two small groups, respectively, for further analyses: I group (unligated side of IMD group), IL group (ligated side of IMD group), C group (unligated side of CMC group) and CL group (ligated side of CMC group). The mice in the IMD and CMC groups were treated with each reagent daily and sacrificed 8 days after the ligation. For assessment of bone resorption, we performed micro-CT and histological analyses. We also carried out real-time PCR to investigate proinflammatory and bone metabolic markers.

Results: There were significant differences for linear bone loss and volumetric parameter in the test (IMD) group compared to the control (CMC) group 8 days after ligation. In terms of the mRNA expression level of gingival tissue, the level of RANKL was significantly suppressed in the IMD group compared to the CMC group. IMD-0354 also tended to suppress the levels of interleukin-1 beta, tumor necrosis factor-alpha, and osteoprotegerin. For histological analysis, the relative numbers of TRAP-positive multinucleated cells decreased significantly in the IMD group compared to the CMC group.

Conclusion: IMD-0354 regulated bone resorption by ligature-induced periodontitis, and it is suggested that the inhibition of IKK via down-regulation of NF kappa-B may provide periodontal patients with an effective approach to prevent or suppress the disease.

Keywords: IKK inhibitor; animal model; inflammation; periodontitis.

MeSH terms

  • Alveolar Bone Loss / diagnostic imaging
  • Alveolar Bone Loss / drug therapy
  • Alveolar Bone Loss / etiology
  • Alveolar Bone Loss / metabolism
  • Animals
  • Benzamides / administration & dosage*
  • Benzamides / pharmacology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / pharmacology
  • Gene Expression
  • Gingiva / metabolism
  • I-kappa B Kinase / antagonists & inhibitors*
  • Injections, Intraperitoneal
  • Interleukin-1beta / metabolism
  • Ligation / adverse effects*
  • Mice, Inbred C57BL
  • Osteoprotegerin / metabolism
  • Periodontitis / diagnostic imaging
  • Periodontitis / drug therapy*
  • Periodontitis / etiology*
  • Periodontitis / metabolism
  • RANK Ligand / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • X-Ray Microtomography

Substances

  • Benzamides
  • Enzyme Inhibitors
  • Interleukin-1beta
  • Osteoprotegerin
  • RANK Ligand
  • RNA, Messenger
  • Tnfsf11 protein, mouse
  • Tumor Necrosis Factor-alpha
  • N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide
  • I-kappa B Kinase